<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401180</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-4737</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-4737</secondary_id>
    <nct_id>NCT00401180</nct_id>
  </id_info>
  <brief_title>Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>Phase I Trial of Weekly Docetaxel and Daily Temozolomide in Patients With Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and temozolomide, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel and&#xD;
      temozolomide in treating patients with metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity profile, dose-limiting toxicity, and maximum tolerated dose of&#xD;
           docetaxel and temozolomide (TMZ) in patients with metastatic cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the activity of docetaxel and TMZ in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral temozolomide once&#xD;
      daily on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of&#xD;
      unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel and temozolomide until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6&#xD;
      patients receive treatment at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>4 cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>4 cycles</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of a nonhematologic malignancy&#xD;
             that is refractory to standard therapy OR for which no standard therapy is available&#xD;
&#xD;
          -  Measurable (by CT scan) or evaluable disease&#xD;
&#xD;
               -  If palliative radiotherapy has been administered, the measurable disease must be&#xD;
                  outside the radiation port&#xD;
&#xD;
          -  Prior brain metastasis allowed provided it was definitely treated with external-beam&#xD;
             radiotherapy, gamma knife, or surgical resection and is clinically stable&#xD;
&#xD;
               -  Repeat MRI or CT scans must demonstrate stabilization of disease 4 weeks after&#xD;
                  the definitive therapy is completed AND there must be no requirement for&#xD;
                  dexamethasone&#xD;
&#xD;
          -  No active CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 4 months&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (epoetin alfa and/or transfusions allowed)&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  PT normal, unless the patient is on warfarin for prior deep vein thrombosis or&#xD;
             pulmonary embolus, requiring INR maintained at 2.0 - 3.0&#xD;
&#xD;
          -  Sodium and potassium normal&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  No decompensated cardiac arrhythmia or other severe cardiovascular disease (i.e., New&#xD;
             York Heart Association [NYHA] class III-IV heart disease)&#xD;
&#xD;
               -  Patients with clinically stable NYHA class III or IV heart disease require&#xD;
                  cardiac clearance&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No infection requiring IV antibiotics within the past 14 days&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No hepatitis B surface antigen or hepatitis C antibody positivity&#xD;
&#xD;
          -  No pulmonary embolus within the past 3 weeks&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 methods of effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 3 courses of prior immunotherapy and/or chemotherapy for metastatic&#xD;
             disease&#xD;
&#xD;
               -  Interferon alfa in the adjuvant setting is not considered a course of prior&#xD;
                  therapy&#xD;
&#xD;
                    -  Patients who relapse on adjuvant interferon alfa must be off therapy for ≥ 3&#xD;
                       weeks&#xD;
&#xD;
          -  No prior stem cell or organ transplantation&#xD;
&#xD;
          -  More than 21 days since prior immunotherapy or chemotherapy&#xD;
&#xD;
          -  At least 21 days since prior hormonal therapy (except luteinizing hormone-releasing&#xD;
             hormone [LHRH] agonists) or radiotherapy and recovered&#xD;
&#xD;
          -  More than 21 days since prior surgery requiring general anesthesia&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Concurrent LHRH agonist therapy allowed&#xD;
&#xD;
          -  Concurrent physiologic replacement steroids allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy or thalidomide&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during study chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Bukowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs. 2008 Dec;26(6):553-9. doi: 10.1007/s10637-008-9153-0. Epub 2008 Jul 15.</citation>
    <PMID>18626572</PMID>
  </results_reference>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert Bukowski</name_title>
    <organization>Cleveland Clinic Taussig Cancer Institute</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

